Literature DB >> 23335087

Cancer statistics, 2013.

Rebecca Siegel1, Deepa Naishadham, Ahmedin Jemal.   

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women. Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate). Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%). The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.
Copyright © 2012 American Cancer Society, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23335087     DOI: 10.3322/caac.21166

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome.

Authors:  N Jewel Samadder; Ken Robert Smith; Jathine Wong; Alun Thomas; Heidi Hanson; Kenneth Boucher; Cathryn Kopituch; Lisa A Cannon-Albright; Randall W Burt; Karen Curtin
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors.

Authors:  Roger T Anderson; Cyllene R Morris; Gretchen Kimmick; Amy Trentham-Dietz; Fabian Camacho; Xiao-Cheng Wu; Susan A Sabatino; Steven T Fleming; Joseph Lipscomb
Journal:  Cancer       Date:  2014-11-04       Impact factor: 6.860

3.  X-linked inhibitor of apoptosis-associated factor l (XAFl) enhances the sensitivity of colorectal cancer cells to cisplatin.

Authors:  Wen-Cui Ju; Guo-Bin Huang; Xiao-Yong Luo; Wei-Hua Ren; De-Qing Zheng; Pin-Jia Chen; Yun-Feng Lou; Bin Li
Journal:  Med Oncol       Date:  2014-11-01       Impact factor: 3.064

4.  α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line.

Authors:  Vanessa Mucchietto; Francesca Fasoli; Susanna Pucci; Milena Moretti; Roberta Benfante; Annalisa Maroli; Simona Di Lascio; Cristiano Bolchi; Marco Pallavicini; Cheryl Dowell; Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-09-08       Impact factor: 8.739

Review 5.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

6.  Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study.

Authors:  Maximilian C Kriegmair; P Honeck; M Theuring; C Bolenz; M Ritter
Journal:  World J Urol       Date:  2017-12-06       Impact factor: 4.226

7.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.

Authors:  Pradeep Kumar Kopparapu; Stephen A Boorjian; Brian D Robinson; Martin Downes; Lorraine J Gudas; Nigel P Mongan; Jenny L Persson
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

Review 8.  Ovarian cancer stem cells: are they real and why are they important?

Authors:  Monjri M Shah; Charles N Landen
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

9.  Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.

Authors:  Madhav Sankunny; Rahul A Parikh; Dale W Lewis; William E Gooding; William S Saunders; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2013-11-25       Impact factor: 5.006

10.  Patient and family member perspectives on searching for cancer clinical trials: A qualitative interview study.

Authors:  Jennifer L Ridgeway; Gladys B Asiedu; Katherine Carroll; Meaghan Tenney; Aminah Jatoi; Carmen Radecki Breitkopf
Journal:  Patient Educ Couns       Date:  2016-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.